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Abstract 
 
Most conventional risk analysis methods rely on a single best estimate of exposure per person 
which does not allow for adjustment for exposure-related uncertainty. Here, we propose a 
Bayesian model averaging method to properly quantify the relationship between radiation dose 
and disease outcomes by accounting for shared and unshared uncertainty in estimated dose. Our 
Bayesian risk analysis method utilizes multiple realizations of sets (vectors) of doses generated 
by a two-dimensional Monte Carlo simulation method that properly separates shared and 
unshared errors in dose estimation. The exposure model used in this work is taken from a study 
of the risk of thyroid nodules among a cohort of 2,376 subjects following exposure to fallout 
resulting from nuclear testing in Kazakhstan. We assessed the performance of our method 
through an extensive series of simulation tests and comparisons against conventional regression 
risk analysis methods. We conclude that when estimated doses contain relatively small amounts 
of uncertainty, the Bayesian method using multiple realizations of possibly true dose vectors 
gave similar results to the conventional regression-based methods of dose-response analysis. 
However, when large and complex mixtures of shared and unshared uncertainties are present, the 
Bayesian method using multiple dose vectors had significantly lower relative bias than 
conventional regression-based risk analysis methods as well as a markedly increased capability 
to include the pre-established “true” risk coefficient within the credible interval of the Bayesian-
based risk estimate. An evaluation of the dose-response using our method is presented for an 
epidemiological study of thyroid disease following radiation exposure.  
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1.  INTRODUCTION 
Proper evaluation of the dose response relationship that takes uncertainty in dose estimation 
into account is a subject of growing importance in epidemiological research [1-6]. Most 
epidemiological studies use conventional regression models based on a frequentist paradigm. 
Those procedures are usually carried out by replacing individual dose estimates with the mean or 
median dose for all individuals in a cohort who share the same exposure attributes. This assumes 
that the unknown true values of individual dose will vary at random about unbiased mean doses 
assigned to individual members of cohort subgroups and that the remaining error structure is 
completely Berkson [7-11]. Some investigators have used the individual median rather than the 
individual mean dose in their regression model [12]. Other investigators have estimated the dose-
response by treating dose uncertainties as mixtures of Berkson and random classical errors [11, 
13-15].  
Few studies, however, have addressed the impact of shared (systematic) uncertainties in 
dose-response analysis. In those cases, methods such as Monte Carlo Maximum Likelihood 
(MCML) methods [16, 17] have been used. Alternatively, mixtures of shared and 
unshared/shared random uncertainties have been addressed using Markov chain Monte Carlo 
(MCMC) methods [18]. 
Overall, the reported effect of dose uncertainties on the slope of the dose-response by these 
more sophisticated methods has been rather small, on the order of a factor of two or less [9, 10, 
16]. However, the cohorts investigated in those studies, predominantly contained Berkson errors 
and relatively small amounts of random classical errors and shared uncertainties. There are, 
however, studies demonstrating that the effect of dose uncertainties on the dose-response can be 
quite large when the dose uncertainty is large. For example, Kopecky et al. [19] discusses 
adjustments to the slope of the dose-response for thyroid cancer for a Russian cohort exposed to 
Chernobyl fallout. The dose uncertainties in individual dose estimates were large (often greater 
than one order of magnitude about a median estimate) and these uncertainties were assumed to 
be completely random classical errors. The risk coefficient (ERR Gy-1), without accounting for 
uncertainty in dose estimation, was 48.7 (95% CI=4.8, 1151). When dose uncertainty was taken 
into account, the risk increased to 138 (95% CI=0.36, 5×108).  
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Li et al. [18] found that the slope of the dose response (ERR Gy-1) was 11.4 (95% CI =2.1, 
59.2) when investigating thyroid neoplasms in the University of Utah cohort exposed to Nevada 
Test Site fallout [11] using regression calibration based on a single set of individual mean dose 
estimates and considering only Berkson errors. However, when using Bayesian MCMC and 
Bayesian Monte Carlo expectation maximization (MCEM) to account for mixtures of unshared 
and shared Berkson errors and unshared classical errors, Li et al. found that the estimate 
increased from 11.4 to either 23.1 (95% CI=3.9, 79) or 63.8 (95% CI=5.4, 240), depending on 
the specific method used. 
It is well understood that estimating individual doses in the absence of direct measurements 
can lead to large and complex uncertainties [20, 21] composed of mixtures of systematic and 
random errors [22]. The most advanced dose reconstruction methods explicitly separate 
systematic (i.e., shared) from unshared sources of uncertainty [20, 22-24]. One such method, the 
two-dimensional Monte Carlo (2DMC), proposed in Simon et al. [22], was used in this work. 
While any method of generating multiple realizations of possibly true cohort dose distributions 
could be used with the Bayesian methodology presented here, we are not aware of the existence 
of dose estimation strategies with this capability other than the 2DMC.  
In this work, we use multiple vectors (sets) of cohort doses for two exposure scenarios drawn 
from a dose reconstruction associated with an epidemiologic study of thyroid disease following 
radiation exposure [24]: one scenario for external dose with limited shared uncertainty and one 
scenario for total dose (external + internal) that includes a complex mixture of shared and 
unshared components. Here, the 2DMC method was used to generate 5,000 vectors of doses for a 
cohort of 2,376 study subjects. We assessed the performance of five different combinations of a 
dose-response analysis method and a specific type of dose data set for each of the two exposure 
scenarios. The two methods assessed were conventional regression and the BMA method which 
is a Bayesian model averaging (BMA) approach to estimate the dose-response [25]. The 
performance tests included: 
(1) Conventional regression using a single vector of individual mean dose estimates, 
(2) Conventional regression using a single vector of individual median dose estimates, 
(3) The BMA method using 5,000 vectors of individual dose estimates, 
(4) The BMA method using 5,000 vectors of conditional individual mean dose estimates, and  
(5) The BMA method using 5,000 vectors of conditional individual median dose estimates.  
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In the comparison of methods presented here, we use the term “conditional mean” or 
“conditional median” to indicate a mean or median dose estimate for an individual that has been 
conditioned on a single sampled value of each dose-model parameter with a value that is shared 
among members of one or more cohort subgroups, and all other unshared parameter values are 
resampled 100 times as a basis for obtaining the conditional individual mean or median dose. 
Conditional individual mean and median doses are used because the process of deriving the 
conditioned value reduces or eliminates classical error within each vector of simulated individual 
doses. To further assess the performance of conditional means and conditional medians, we 
intentionally introduce additional amounts of classical error for testing with the BMA method.  
 
2. METHODS 
 
2.1. Dose Estimation Method 
The construction of a radiation dosimetry system involves the application of principles of 
radiation exposure and dose assessment to estimate radiation doses received by individuals from 
past events [23]. Some studies only require a relatively simple dosimetry system, as is usually 
the case with controlled exposures in medicine. In those studies, a simple approach using either 
Monte Carlo or analytical error propagation methods will likely suffice as a means to assess 
uncertainty since there is often no need to distinguish between shared and unshared errors.  
Here, we used a two-dimensional Monte Carlo (2DMC) dosimetry method that is designed to 
explicitly address random variations and systematic biases in a dosimetry system separately. 
Upon correct application of the 2DMC method, each dose vector is internally consistent, that is, 
doses for individuals in a cohort with common exposure attributes are properly correlated with 
each other. This method is particularly useful for complex dosimetric evaluations of 
environmental and occupational exposures that are designed to support evaluation of the dose-
response relationship [22]. 
The radiation doses we used for the simulation study are estimates of external and internal 
radiation dose to the thyroid gland from exposure to radioactive fallout from nuclear testing 
conducted from 1949-1962 at the former Soviet nuclear weapons test site in Semipalatinsk, 
Kazakhstan. Exposures due to radioactive fallout were simulated for residents of eight villages in 
a study of thyroid disease performed by Land et al. [26] but using updated radioactive fallout 
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exposure models [24, 27-29]. The external dose assessment estimates the time-integrated 
exposure modified by time spent indoors and building shielding characteristics. For external 
dose, the time of transit of fallout from the detonation site to each of the eight villages as well as 
the village-and test-specific ground-level exposure rates are important shared errors. The study 
also estimates the total dose which is a summation of the external dose and the internal dose, the 
latter which is a quantitative estimate of internal irradiation that arises from consumption of food 
products contaminated with radioiodines [24, 28]. The internal dose would also have significant 
shared errors including the ground-level village- and test-specific exposure rate, the parameter 
describing the interception of fallout by plants (a function of particle size which is related to 
downwind distance at the site), and the coefficients describing the transfer of radioiodine from 
feed to each type of animal milk.  
For the purpose of testing the performance of the risk analysis methods listed, we simulated 
5,000 alternative, possibly true vectors of external and internal doses for the cohort using the 
2DMC method. Each dose vector contains a single dose estimate for each subject in the cohort. 
The 2DMC method was used to ensure that the proper correlations between doses for individuals 
with common exposure attributes were maintained.  
Table 1 of this paper describes the variability and uncertainty in the 5,000 vectors of 2,376 
simulated individual doses, conditional individual mean doses and conditional individual median 
doses produced by the 2DMC algorithm, summarized as a 95% CI. The cumulative distributions 
of the 2DMC multiple realizations of cohort dose vectors are presented in Fig. 1. 
 
2.2. Bayesian approach for dose-response with complex dosimetry from a 2DMC algorithm 
Because the 2DMC dose algorithm is able to effectively separate shared from unshared 
uncertainties in a dose reconstruction, a dose-response methodology is needed to accommodate 
the multiple realizations of cohort dose vectors. For that reason, we consider an approach for 
dose-response analysis under the statistical paradigm of model uncertainty, which goes beyond 
simple measurement error models. In this paper, model uncertainty was assumed to arise from 
the uncertainty due to dose estimation rather than uncertainty in the shape of the dose-response 
model. In this work, we have assumed a linear dose-response model.  
Here, it is our a priori expectation that at least a few of the simulated vectors of doses should 
be reasonable approximations of the true vector of exposures and, thus, we should be able to 
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evaluate and compare each of the alternative vectors of cohort dose to find the best fit. Due to 
complexity of the exposure model and the uncertainty of many of the exposure-related 
parameters, however, we cannot assume that the perfect true vector of doses is included within 
the multiple realizations of dose produced by the 2DMC dose estimation algorithm. For that 
reason, we use a Bayesian model averaging (BMA) [25] approach to estimate the dose-response. 
Some detail about the relationship between our problem and the paradigm of Bayesian model 
uncertainty is presented in the Appendix. 
The BMA method employed in this paper obtains a posterior probability of the slope of the 
dose-response, by (i) considering all realizations of external dose and total thyroid dose vectors 
produced by the 2DMC dose reconstruction system, and (ii) evaluating the goodness of fit of 
each dose vector with the specified disease outcome. Our approach has an advantage over 
conventional dose-response analysis that use a single dose for each study subject, in that it can 
address very complex estimations of exposure which include varied patterns of shared and 
unshared uncertainty in the dose estimation parameters. 
Our main goal is to estimate the radiation risk coefficient of a linear dose-response model, , 
and its confidence interval, as well as the credible interval for the Bayesian method, accounting 
for sampling uncertainty as well as uncertainty in dose estimation.  
In this work, we consider a binary disease status variable for thyroid nodules with a logistic 
regression model and other covariates, the same model formulation as used in Land et al. (2008). 
For simplicity, we excluded effect modifiers in this paper. We assume, thus, that the probability 
of disease given covariates X and dose D is given by the expression 
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where Xj, j=1,…, J, are covariates, and  is the excess relative risk per Gy (ERR Gy-1). 
Since uncertainty in dose estimation is represented by K dose vectors, we use a data 
augmentation approach to deal with multiple realizations of dose vectors. This is implemented in 
the form of a dose vector selection parameter, , that indicates which dose vector is used in the 
likelihood for a cohort of N individuals, given by  
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In order to perform Bayesian inference, we must formulate prior distributions for all 
uncertain model parameters. For prior distributions, we use a normal distribution for the α 
parameters in equation (3) with a large variance in order to be a proper but non-informative 
prior. For a positive slope of the dose-response, , in equation (4), we use an exponential 
distribution with a large mean. The dose vector selection parameter, , has a multinomial 
distribution, Multinomial() in equation (5). The probability vector, , has a hyper-prior 
distribution given by a Dirichlet distribution in equation (6), Dirichlet(1,...,1), so that every dose 
vector has an equal a priori probability to be the possibly “true” dose vector.  
Priors: =(1,…,J),  j ~ N(0, 1000),  j=1,2,..J, (3) 
 ~ exponential(100), (4) 
~ Multinomial(), (  {1,…,K}), (5) 
 = (1,…,K ) ~ Dirichlet(1,…,1) .  (6) 
 
The joint posterior distribution is defined as follows: 
p(α,,|y,X,Dose)  l(α,,|y,X,Dose)p(α)p()p() . (7) 
The posterior inference is obtained from a Markov chain Monte Carlo (MCMC) calculation. 
Since the likelihood is formulated with a logistic function, full conditional distributions of the 
parameters do not have a closed form solution of known distributions. Therefore, the Metropolis-
Hastings (MH) method is generally suitable to sample from the posterior distribution of the 
parameters of interest. Along with the posterior inference for the slope of the dose-response 
parameter, , a relative selection frequency (Bayesian weight) for a specific dose vector is 
obtained from the posterior distribution of the dose vector index variable, γ. The Bayesian 
weight, 


K
m
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1
),,|(),,|(  , k=1,…,K, is a relative 
measure of the goodness-of-fit of each dose vector. For those dose vectors that are relatively 
close to the unknown vector of true doses, Bayesian weights will typically be relatively larger 
than those produced for the remaining dose vectors that are less precise approximations of the 
(unknown) vector of true dose.  
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In situations when the magnitude of uncertainty in dose estimation is much less than in our 
example based on the total thyroid dose in the Kazakhstan cohort, we can use either WinBUGS 
[30] or JAGS [31] for Bayesian computation. For example, Poisson regression and negative 
binomial regression models were used via JAGS with 1,000 dose vectors that accounted for 
shared error in Little et al. [32].  
When doses are estimated from historical exposure situations and numerous sub-models are 
necessary to account for the important pathways of exposure, we are likely to have a complex 
landscape of posterior distributions for the parameters of the dose-response model which, in turn, 
produces a multimodality of the posterior distribution of the slope of the dose response. In 
situations such as this that would generally require MCMC methods such as the Metropolis-
Hastings (MH) and Gibbs sampling methods, we often face a local-trapping problem which can 
lead to large biases in parameter estimation and a very narrow confidence interval about the 
slope, . To overcome that problem in our work, we used an advanced MCMC method referred 
to as a Stochastic Approximation Monte Carlo (SAMC) method [33]. More detail of SAMC is 
described in the Appendix. 
 
3. SIMULATION STUDY 
This section describes the process of developing 90 test cases for each of two exposure 
scenarios in order to assess the performance of the dose-response methods. As noted earlier, the 
primary difference in the two exposure scenarios is the markedly different amounts of shared and 
unshared uncertainty in the parameters of the exposure models used to estimate individual dose. 
The 90 test cases are, simply, 90 different simulated sets of disease status for the entire cohort. 
Each set is considered to be a “true” set for testing purposes. Each “true” disease set is simulated 
using a pre-selected vector of “true” dose (one dose per subject) and a pre-specified “true” slope 
of a linear dose response relationship, along with covariates of the baseline risk from the 
Kazakhstan epidemiological study [24]. 
 
3.1.  Specifics of Dose Simulation 
For our Exposure Scenario 1, we used 5,000 vectors of simulated individual thyroid doses 
from external exposure obtained from the Kazakhstan epidemiologic study [24]. The thyroid 
dose estimates from external exposure are associated with relatively small amounts of dose 
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uncertainty and small amounts of shared uncertainty contributing to the total uncertainty in 
individual dose estimation (see Table 1 and Fig 1). 
For our Exposure Scenario 2, we used 5,000 vectors of simulated individual total thyroid 
dose (external + internal exposure). In contrast to Exposure Scenario 1 (external exposures), 
Exposure Scenario 2 (total exposure) is associated with very large amounts of dose uncertainty, 
with substantial shared uncertainty contributing to the overall uncertainty in each individual's 
dose (see Table 1 and Fig. 1).  
 
3.2. Simulation of multiple alternative sets of disease status 
For the purposes of performance testing, we simulated multiple alternative realizations of a 
“true” set of disease status (i.e., the disease status for the 2,376 individuals in the cohort). Each 
simulated set of disease status was produced using one of the 5,000 vectors of doses for the 
cohort, one of three pre-specified values of a "true" slope, , (ERR Gy-1=3,12, and 20), and 
covariates that affect the baseline risk of thyroid nodules (i.e., age at time of screening and sex). 
The values for covariates are 2 for age at time of screening, 1.5 for male, and 3 for female. Thus, 
5,000 sets of "true" disease status were simulated for each of the three pre-specified “true” value 
of the slope of the dose response and for each exposure scenario, producing a total of 15,000 
simulated sets of "true" disease status per exposure scenario and 30,000 simulated “true” disease 
status sets overall. Each simulated set of disease status is a potential candidate for performance 
testing of the two methods of dose response estimation. The following section describes the 
procedure used to select 180 simulated sets of “true” disease status for use in performance testing 
to compare the dose response estimates produced by conventional regression methods with the 
Bayesian method that uses multiple vectors of cohort doses. 
 
3.3. Selection of specific disease status sets for performance testing 
While it is feasible to use all 30,000 simulated sets of disease status to test the performance 
of the conventional regression methods that use a single vector of mean or median doses (Figs. 3 
and 4), it is prohibitive to perform 30,000 tests of the Bayesian dose response methods, due to 
excessive computational requirements. Therefore, we selected a subset of simulated disease 
status sets to produce a representative range of test conditions that was balanced for subsequent 
performance testing of the different methods of dose response analysis. 
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For each of the two exposure scenarios, we selected a subset of 90 sets of disease status, 30 
for each of the three pre-specified “true” value of the slope. The selection process we used was 
as follows: 
 
(i) For each of the three pre-specified “true” values of the slope of the dose response, we 
simulated 5,000 “true” sets of disease status and estimated the slope of the dose 
response for each disease status set using conventional regression with individual 
median doses. 
(ii) We ordered the 5,000 estimated slope values (ERR Gy-1) in ascending order and 
divided the ordered sets into ten groups of 500 sets of estimated slope. 
(iii) From each of the ten groups of 500 sets of estimated slopes, we selected three at 
random and identified the corresponding a set of simulated disease status sets to 
produce 30 “true” simulated sets of disease status for each of three pre-specified “true” 
values of the slope, for a total of 90 sets of disease status selected per test scenario (180 
sets of disease status selected overall among both test scenarios).  
 
In the selection procedure described above, the subset of 30 disease status sets are 
representative of the overall range of disease status sets and are symmetrically balanced about 
the specific disease status set that has an estimated slope equal to the “true” slope. This balance 
avoids a bias in the selection of sets of disease status which have estimated slopes (using 
conventional regression with individual median doses) towards over-or under-estimation of the 
“true” slope.  
The selection procedure essentially involves pre-testing conventional regression using 
median doses with all 30,000 simulated sets of disease status. Thus, our reported test results for 
this method are effectively pre-determined and will have a pre-determined high rate of successful 
outcomes. About 50% of the disease vectors selected for testing in Exposure Scenario 2 will 
have corresponding 95% confidence intervals that included the prescribed “true” slope (See 
Table 2). Therefore, the test results for conventional regression using median doses should be 
considered a baseline when comparing the test results obtained with other methods of dose 
response evaluation. 
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3.4. Comparison of performance of Bayesian procedure and conventional regression models 
 In the performance testing conducted in this paper, two basic types of statistical methods 
were used to determine the dose-response of the simulated “true” sets of disease status: (1) 
conventional regression using a single vector of individual doses, and (2) Bayesian model 
averaging (BMA) using multiple dose vectors produced from the 2DMC dose estimation 
algorithm. In our analysis with the conventional regression-based method, we used a single 
vector of individual mean or individual median doses obtained from 5,000 dose realizations for 
each member of the cohort. 
For each simulation of a disease status set, one cohort dose vector out of the 5,000 simulated 
dose vectors produced by the 2DMC dose estimation algorithm was pre-selected as a “true” 
cohort dose vector. This “true” dose vector used to simulate a selected set of disease status is 
excluded from the full 5,000 dose vectors prior to use of the BMA method for dose response 
analysis, reflecting the condition that the true exposure model is not included in our model 
uncertainty paradigm (see Appendix). The BMA method thus uses 4,999 dose vectors to evaluate 
the dose response for a given “true” set of simulated disease status. 
Performance testing consisted of comparing the results of dose-response estimation produced 
by conventional regression and the BMA method for each of the simulated “true” sets of disease 
status selected for each of two test scenarios. These tests were conducted to determine whether 
the value of the “true” slope was captured within (i) the 95% confidence interval (CI) of the 
slope parameter, , estimated from the conventional regression model, and (ii) the Bayesian 
credible interval of the posterior distribution of the slope parameter, , estimated from the BMA 
method. Bayesian parameter estimates and their corresponding 95% Bayesian credible interval 
were obtained based on 40,000 posterior samples after 10,000 burn-in iterations (burn-in is an 
initial set that is not used for inferences). Hereafter, we used the notation CI for both confidence 
interval and Bayesian credible interval. 
 
3.5. Multiple vectors of conditional mean and median dose 
Because of our concern that each of the simulated cohort dose vectors from the 2DMC dose 
estimation procedure might inadvertently over-estimate inter-individual variability of true doses 
and, thus, introduce non-intended classical error into the analysis, multiple conditional individual 
mean doses and conditional individual median doses were also produced. A vector of conditional 
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individual mean and median doses was obtained (separately) after resampling 100× all 
parameters used for dose-estimation specified as representing unshared uncertainty in each 
subject’s dose. This resampling was “conditioned” on a fixed set of dose-model parameter values 
that were shared among members of cohort subgroups. Selection of a fixed set of shared 
parameter values and resampling 100× all unshared parameters for each of all 2,376 individuals 
in the cohort was repeated 5,000 times to produce 5,000 vectors of conditional individual mean 
and median doses. Each vector of conditional individual mean or median doses is assumed to be 
a possibly “unbiased” central estimate of doses for subgroups of individuals sharing the same 
exposure attributes; all remaining uncertainty is attributed to random variation of the unknown 
individual true dose about the possibly unbiased central value of dose assigned to members of 
the subgroup (i.e., all remaining uncertainty is assumed to be 100% Berkson). 
 
4. RESULTS  
 
4.1. Inclusion percentage of the “true” test slope within the 95% CI slope estimates  
As one indicator of performance of each of the methods of dose response, we used the 
percentage with which the pre-specified “true” slope was captured by the 95% CI of the 
computed slope estimate (Table 2). Since conventional regression with the single vector of 
individual median doses was used to select the set of simulated disease status used for testing, 
the test results obtained with this method should be considered as a benchmark against which the 
other methods are compared. 
 
4.2. Testing of conventional regression analysis methods with a single vector of mean doses 
against those using median doses 
As part of performance testing, we first compared conventional regression using a single 
vector of individual mean doses with the same method using a vector of median doses. For both 
exposure scenarios, the inclusion percentages for the single vector of individual mean doses were 
lower than those for the individual median doses though the difference was small, 91.1% for the 
mean doses compared with 94.4% for the median doses (Table 2, Fig. 4, and Supplementary 
Fig. 1). However, for Exposure Scenario 2, the difference in the inclusion percentage between 
these two data sets was dramatic, 12.2% for means compared to 51.1% for medians.  There was 
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also strong evidence of a marked systematic bias in the dose response estimated by the individual 
mean doses towards underestimation of the “true” slope of the test data (Fig. 5, also see 
Supplementary Fig. 2).  
In order to examine the representativeness of the selected disease status sets used for testing, 
we calculated inclusion percentages of the “true” value of the slope with conventional regression 
using single vectors of mean and median doses for all generated disease status sets. Inclusion 
percentages are shown in parentheses in Table 2. Inclusion percentages obtained for the subset of 
30 selected disease sets were comparable to those obtained for all 5,000 disease sets simulated 
using a “true” value of the slope. 
We investigated possible reasons why conventional regression with the mean doses showed 
an apparent inferior performance compared with the results obtained with the median doses in 
Exposure Scenario 2 (Fig. 3, also see Supplementary Fig. 2). In Figs. 2 and 3, the slopes (ERR 
Gy-1) for all 5,000 disease sets were estimated using both mean doses and median doses. While 
the slope estimates with median doses were symmetrically distributed among the multiple 
disease status sets for both Exposure Scenario 1 and 2, slope estimates using mean doses were 
highly skewed in Exposure Scenario 2. The skewness for the mean doses seen for Exposure 
Scenario 2 (Figs. 3, 5, and Supplementary Fig. 2) is the result of very high uncertainty in each 
subject’s dose, with the 5,000 dose estimates for each study subject approximating a lognormal 
distribution with about 30% of the cohort having GSDs greater than 3.0 and with 5% having 
GSDs greater than 4.0. This high uncertainty in each individual’s total thyroid dose is the 
consequence of both shared and unshared sources of uncertainty contributing to the distribution 
of dose estimates for each person.  
With a wide distribution of dose estimates for each individual that approximates a lognormal 
distribution, the mean of that distribution will be a much larger value than the median. Because 
this wide distribution is the outcome of a large combination of multiple sources of dosimetric 
uncertainty (in addition to random variability of true dose among individual members of cohort 
subgroups sharing the same exposure attributes), the individual mean dose for members of any 
subgroup will be biased high with respect to the true mean dose for that subgroup. Thus, when a 
single vector of individual mean doses is obtained from 5,000 dose realizations per study subject, 
and when these dose realizations contain a combination of major sources of uncertainty in 
addition to random inter-individual variability of true doses, conventional regression using this 
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vector of mean doses will produce a systematic under-estimation of the majority of the “true” 
test slopes of the dose response. 
 
4.3. Comparison of conventional regression using median doses with Bayesian methods 
When we compared the performance results obtained with the single vector of cohort median 
doses against the three Bayesian model averaging approaches for Exposure Scenario 1 (Table 2), 
we found equally high inclusion percentages (95.6%) for all three Bayesian methods, comparable 
to the conventional regression with median doses (94.4%). These high inclusion percentages 
reflect the relatively small amounts of uncertainty associated with the external thyroid dose 
estimates in the Kazakhstan study [24].  
In contrast, for Exposure Scenario 2 (total dose), the three Bayesian methods showed 
substantially higher inclusion percentages (70 to 91%) than did conventional regression using the 
single vector of cohort median doses (52.2%). The Bayesian approach using multiple cohort 
vectors of conditional individual mean doses and multiple vectors of conditional individual 
median doses produced very high inclusion percentages of 88.9 and 91.1%, respectively. These 
results were substantially improved over the Bayesian approach using simulated individual doses 
(70%).  
In about 9% of the cases where the Bayesian approach using the conditional individual 
median dose vectors did not contain the "true" test slope of the dose response within its 95% CI, 
the other dose response methods failed as well. We believe that these cases may represent special 
situations with low statistical power to detect an underlying true effect.  
 
4.4. Evaluation of the relative bias of the slope estimates 
We also computed the relative bias associated with the estimate of the slope of the dose 
response in each test (Table 3). Relative bias is calculated as absolute bias (estimated slope – 
“true” slope) divided by the “true” slope. The performance of the various dose-response 
evaluation methods can be compared using the magnitude of relative biases. In Exposure 
Scenario 1, the magnitudes of relative biases were small for all methods of dose response, a 
finding that is consistent with the high inclusion percentages in Table 2.  
However, in Exposure Scenario 2, the Bayesian method with conditional individual median 
dose vectors showed the smallest relative bias (0.29). This can be compared with 0.31 obtained 
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with the Bayesian approach using conditional mean doses and with 0.40 obtained with the 
Bayesian approach using simulated individual doses. In contrast, the conventional regression 
analyses using a single vector of mean doses and median doses produced an overall relative bias 
of 0.66 and 0.46, respectively. In Exposure Scenario 2, most of the relative bias for conventional 
regression using mean doses is due to a systematic tendency to overestimate the “true” test slope, 
while conventional regression using median doses results, as expected, in a symmetrical over- 
and under-estimate of the “true” test slope (Figs. 4 and 5 and Supplementary Figs. 1 and 2). This 
expectation arises because conventional regression using individual median doses was used to 
select the subset of simulated disease vectors used for testing. 
 
4.5. Evaluation of the width of the 95% CI’s 
Here we discuss the magnitude of uncertainty associated with the various estimates of the 
slope of the dose response using the half-width of 95% CI (Table 3). Exposure Scenario 1 
contains relatively small differences between the width of the CI between conventional 
regression and any of the Bayesian methods. However, in Exposure Scenario 2, the difference 
between the half-width of the CI for conventional regression using a single vector of median 
doses and the Bayesian approach using multiple dose vectors was more than double (3.8 
compared with 8.1). In addition, the half-width of the CI comparing conventional regression 
using mean doses to conventional regression using median doses was also more than double 
(1.72 compared with 3.8). The larger values for the half width of the CI for the Bayesian 
methods reflects wider CI’s that contain the influence of uncertainty in dose estimation as well as 
uncertainty in the fit of the dose response to the disease status set. 
Interestingly, the half-width of the CI for conventional regression with a single vector of 
mean doses decreased in Exposure Scenario 2 compared with Exposure Scenario 1. In Exposure 
Scenario 2, because of the presence of very large uncertainties in the simulated individual doses, 
the values of the individual mean doses are larger than the values of individual median doses. 
These larger individual mean dose estimates most often produced under- estimates of the “true” 
test slope of the dose-response (Table 1). This caused the half-width of the 95% CI of the 
estimate of the slope to shrink in size.  
We also examined the relative width of the ratio of the upper CI of the slope estimates to the 
estimate of the slope (Table 2). These relative widths were very stable across different values of 
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the test slope. The relative width of the upper CI from the Bayesian methods were about 6% and 
35% larger in Exposure Scenarios 1 and 2, respectively, than those produced by the conventional 
regression analysis with median or mean doses. As with the results for the half-width of the CI, 
larger values of the relative width of the upper bound of the CI for the Bayesian analyses, reflects 
uncertainty in dose estimation as well as uncertainty in the fit of the dose response model to the 
test disease status set. The effect of dose uncertainty is not included in the 95% CI’s produced by 
conventional regression analysis using a single vector of individual mean or individual median 
doses. 
 
4.6. Evaluation of simulated classical errors 
For the conventional regression analysis methods, the presence of classical error in dose 
estimation has been demonstrated to bias the estimate of the slope of the dose response towards 
the null [4]. In this paper, we examined the effect of classical error on the dose response 
determined by the Bayesian method. Additional amounts of classical error were intentionally 
introduced, via simulation, into the 5,000 2DMC dose vectors using a multiplicative lognormal 
classical error factor. This factor was defined by a GM of 1.0 with increasing values of the 
geometric standard deviation (GSD) to simulate increasing amounts of unshared random 
variability in dose estimation due to random factors other than true inter-individual variability of 
true dose.  
The lognormal classical error factor was applied within the unshared part of the 2DMC dose 
calculation for the total thyroid dose. For the Bayesian method using 4,999 vectors of simulated 
individual doses, the lognormal factor was sampled once for each of individual doses within a 
dose vector. This was repeated per individual for each successive dose vector. For the Bayesian 
approach with 4,999 vectors of conditional individual mean and median doses, the lognormal 
classical error factor was applied per individual within each of the conditional 100× resampling 
of unshared parameters. This procedure inflated the variability of each individual dose 
distribution within each conditional dose vector.  
Values of the GSD for the lognormal classical error simulation factor ranged from 1.0 (no 
classical error), to 1.3 (low), 1.5 (modest), 2 (high), and 3 (very high). In Fig. 6 we show how the 
slope estimates and corresponding 95% CIs are affected by increasing amounts of classical error. 
All Bayesian approaches to dose response analysis showed increasing attenuation in the 
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estimated slope of the dose response as the amount of simulated classical error increased, except 
the Bayesian approach using multiple vectors of conditional individual median doses. The 
response to the simulation of multiplicative classical error was most pronounced with the 
Bayesian approach using multiple vectors of simulated individual doses. 
In summary, under conditions of high and complex dose uncertainty (as represented by the 
total thyroid doses in Exposure Scenario 2), all three Bayesian approaches performed markedly 
better in our simulation tests than did the more conventional regression analysis using a single 
vector of mean or median doses. However, all five approaches performed very well when 
uncertainty in individual doses was low and when shared sources of uncertainty were small. 
Application of these methods to an actual set of individuals with thyroid nodules and thyroid 
cancer is demonstrated in Land et al. [24]. 
 
5. Application to the Actual Prevalence of Thyroid Nodules 
 
The above tests were based on simulation of the prevalence of thyroid nodules that reflected 
a pre-determined “true” slope of the dose response.  To demonstrate the utility of the Bayesian 
model averaging method with multiple realizations of cohort doses, we proceeded to apply this 
method to the actual observed cases of thyroid nodules in this cohort for which there were 177 
cases in males and 571 cases in females among 2,376 individuals [24].   
As in Land et al. [26], we used same model as follows:  
})Zexp{Y1(]Xαexp[Odds kkjjii   . 
The subscripted Greek letters i, j and k denote unknown parameters, and the corresponding 
subscripted capital letters Xi, Yj and Zk denote potential risk factors, radiation dose (external and 
internal doses given separately), and gender variable (-1 for male and 1 for female) for effect 
modifiers, respectively. The exponential expression exp{iXi} represents the baseline odds, i.e., 
when the radiation dose is zero. The odds ratio (OR) is the ratio of the odds to the baseline odds,  
 
}exp{1   kkjj ZYOR   
 
and the excess odds ratio (EOR) is the odds ratio minus 1.  
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The previous 2008 study [26], which used conventional regression with a single vector of 
“best estimate” individual thyroid doses, showed that the slope of the dose response (EOR Gy-1) 
for external exposure was higher (prior to modifying by sex), but not statistically significantly 
different from internal exposure. We get similar results to those reported in 2008 study, using 
conventional dose-response analysis with a single vector of arithmetic mean dose per person. 
However, when a single vector of individual median doses is used with conventional regression, 
the central estimate of the slope of the dose response for internal exposures is about a factor of 5 
higher than that obtained using the single vector of “best estimate” doses from the 2008 paper 
[26].   
In contrast to conventional regression-based methods with a single vector of individual dose 
estimates, our Bayesian model averaging method produced risk estimates for internal exposures 
that were equal to or higher than the risk estimates for external exposures.  However, because of 
the large overlap of 95% CIs, differences in risk estimates between internal and external 
exposure were not statistically significant.  Unlike the 2008 results [26], the dose responses for 
external exposure (prior to modification by sex) were not statistically significant (24). Central 
estimates of the EOR Gy-1 for external exposure prior to modification by sex (1.5 to 1.6) were 
comparable among all Bayesian analyses.   
The Bayesian model averaging method did confirm the presence of a significantly larger EOR 
Gy-1 for males than for females.  Previously in 2008 [26] this difference was reported to be a 
factor of about 11, with the EOR Gy-1 for males being larger than that for females.  In the present 
analysis, the EOR Gy-1 for males, 9.99 (95% CI 2.33, 19.1) increased by almost a factor of 30 
over that for females, 0.35 (95% CI, 0.000011, 1.0).  The above results are based on Bayesian 
model averaging with multiple (5,000) vectors of conditional individual median doses since we 
this approach performed the best in our simulation tests compared with Bayesian model 
averaging using multiple vectors of simulated individual doses or with conditional individual 
mean doses. Additional description of this cohort and further details of the application 
conventional regression analysis and Bayesian model averaging with multiple cohort dose 
vectors to evaluate the dose response of the actual prevalence of thyroid nodules can be found in 
Land et al. [24].  
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6. CONCLUSIONS 
 
We have demonstrated the use of a Bayesian-based risk analysis method that can be used with 
multiple realizations of possibly true cohort doses produced from a dosimetry system, e.g., the 
2DMC dose reconstruction method, which explicitly accounts for shared and unshared errors in 
dose reconstruction. We have shown that unlike simpler and more traditional frequentist-based 
dose-response calculation strategies, e.g., regression calibration, that are adequate when shared 
errors are small, this Bayesian method gives more reliable and robust results when the shared 
error among study subjects is substantial. The Bayesian analysis with conditional individual 
median doses captured the "true" slope of the dose response without attenuation, even when there 
were large amounts of simulated classical error introduced into the dose estimates. For this 
reason, we recommend that the Bayesian approach using multiple vectors of conditional 
individual median doses as our preferred method for quantifying the dose response when dose 
uncertainties are large and when the amount of uncertainty shared across cohort subgroups is 
substantial.  
Application of our Bayesian method to the actual prevalence of thyroid nodules in the 
Kazakhstan nuclear test site cohort demonstrated marked differences from what was reported 
previously using conventional regression with a single vector of dose estimates.  The risk per 
unit dose from internal exposure increased by about a factor of six and the dependency of risk on 
sex increased from a previously reported factor of 11 to nearly 30 with males having higher 
excess odds ratios per unit dose than females. We believe these results to be more reliable 
because of the superior capabilities of the Bayesian Averaging Method as demonstrated through 
the extensive simulation tests performed and discussed in Section 4. This represents the first 
application of multiple realizations of uncertain cohort doses combined with a Bayesian Model 
Averaging method to evaluate risk in an exposed cohort exposed to ionizing radiation. 
Clearly there are special cases when dose uncertainty is relatively small and where sources of 
shared uncertainty are minor, as is the case for external doses for the Kazakhstan study cohort. 
Under those situations, the conventional dose-response method using a single vector of 
individual median doses produced results comparable to the Bayesian approaches. Even when 
dose uncertainties were small, conventional dose-response estimation using a single vector of 
individual median doses performed marginally better than with a single vector of individual 
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mean doses. Thus, the primary utility of conventional dose-response estimation using a single 
vector of individual median doses appears to be in situations where (a) dose uncertainty is 
relatively small and (b) dose uncertainty is mainly the result of random unshared errors among 
individuals, with only a minor contribution of shared sources of dose uncertainty. 
Radiation dosimetry is but one type of exposure analysis where substantial individual and 
shared errors may be involved. Exposures due to other occupational hazards and, occasionally, 
due to exposure that affect members of the public, may also be highly uncertain. The methods, 
principles, and findings discussed here should, in principle, equally apply well, whenever 
uncertainty in an epidemiologic study is an important concern. 
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Table 1. Estimates of the distribution of individual doses in the Kazakhstan cohort [from Land et al. (2014)] 
Exposure Scenario  1: External thyroid dose 
Cohort dose 
Individual 
mean 
valuesa 
Individual 
median 
valuesb 
2DMC Individual 
Dose Realizationsc 
2DMC Conditional Individual 
Mean Dosesd 
2DMC Conditional Individual 
Median Dosese 
95% CI 95% CI 95% CI 
Minimum(Gy) 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
Maximum (Gy) 5.4E-01 5.0E-01 4.4E-01 1.3E+00 3.3E-01 8.6E-01 3.1E-01 8.2E-01 
Median (Gy) 3.7E-02 3.5E-02 2.1E-02 3.7E-02 2.3E-02 4.6E-02 2.2E-02 4.3E-02 
Mean (Gy) 5.6E-02 5.2E-02 4.4E-02 7.1E-02 4.4E-02 7.1E-02 4.1E-02 6.7E-02 
Variance (Gy2) 4.5E-03 3.7E-03 3.2E-03 1.0E-02 2.6E-03 8.3E-03 2.3E-03 7.3E-03 
Exposure Scenario 2: Total thyroid dose 
Cohort dose 
Individual 
mean 
valuesa 
Individual 
median 
valuesb 
2DMC Individual 
Dose Realizationsc 
2DMC Conditional Individual 
Mean Dosesd 
2DMC Conditional Individual 
Median Dosese 
95% CI 95% CI 95% CI 
Minimum(Gy) 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 
Maximum (Gy) 4.8E+01 1.2E+01 1.9E+00 1.5E+02 8.8E-01 4.5E+01 7.1E-01 3.6E+01 
Median (Gy) 1.6E-01 1.0E-01 7.0E-02 1.6E-01 8.3E-02 2.4E-01 6.6E-02 1.6E-01 
Mean (Gy) 4.5E-01 1.7E-01 1.2E-01 2.2E+00 1.2E-01 2.3E+00 9.5E-02 1.2E+00 
Variance (Gy2) 5.6E-01 3.7E-02 2.5E-02 8.1E+01 1.6E-02 3.3E+01 9.7E-03 1.0E+01 
 
A comparison of cohort dose estimates using a single vector of 2376 
    a individual mean doses and  
    b individual median doses, with a 2DMC dose estimation producing 5000 vectors of 2376  
    c simulated individual doses  
    d conditional individual mean doses, and  
    e conditional individual median doses.  
The single vector of individual mean and median doses are obtained from 5000 dose realizations per each of 2376 study subjects.
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Table 2. Inclusion percentage (%) of “true” value of the slope (ERR/Gy) summarized from 90 simulated “true” sets of disease status per exposure scenario. 
Exposure Scenario 1 (external thyroid dose) Exposure Scenario 2 (total thyroid dose) 
Method Conventional regression Bayesian method Conventional regression Bayesian method 
“True” slope 
(ERR/Gy) Mean dose
a Median doseb Originalc CMd CMDe Mean dosea Median doseb Originalc CMd CMDe 
20 86.7 (91.3)f 93.3 (96.6) f 93.3 93.3 93.3 10.0 (12.1) f 50.0 (52.2) f 63.3 83.3 90.0 
12 90.0 (95.3) 93.3 (98.6) 96.7 93.3 93.3 13.3 (12.6) 50.0 (49.5) 66.7 86.7 86.7 
3 96.7 (99.9) 96.7 (99.9) 96.7 100 100 13.3 (11.5) 53.3 (55.4) 80.0 96.7 96.7 
Overall 91.1 (95.5) 94.4 (98.4) 95.6 95.6 95.6 12.2 (12.1) 51.1 (52.4) 70.0 88.9 91.1 
 
Conventional regression analysis using a single vector of 2,376 doses (one per subject) 
(a) individual mean doses 
(b) individual median doses 
 
Bayesian Model Averaging using 4,999 cohort dose vectors of 2,376 doses (one per subject per vector) 
(c) simulated individual doses (Original) 
(d) conditional individual mean doses (CM) 
(e) conditional individual median doses (CMD) 
f Parentheses denote inclusion percentage using all 5,000 simulated “true” disease status sets produced for each prescribed “true” slope of a linear dose-response 
for performance testing of conventional regression analysis methods. 
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Table 3. Relative Bias, Half-width of CI, and Relative Upper Bound of CI summarized from 90 
performance tests using simulated “true” sets of disease status for Exposures Scenarios 1 and 2. 
Relative bias 
Scenario 1 (external thyroid dose) Scenario 2 (total thyroid dose) 
Method Conventional regression Bayesian method 
Conventional 
regression Bayesian method 
“True” slope 
(ERR/Gy) 
Mean 
dosea 
Median 
doseb Original
c CMd CMDe mean dosea 
median 
doseb Original
c CMd CMDe 
20 0.15 0.14 0.14 0.13 0.13 0.62 0.35 0.38 0.30 0.27 
12 0.14 0.14 0.15 0.13 0.14 0.66 0.39 0.38 0.29 0.28 
3 0.18 0.20 0.17 0.18 0.20 0.70 0.65 0.42 0.35 0.32 
Overall 0.16 0.16 0.16 0.15 0.16 0.66 0.46 0.40 0.31 0.29 
Half-width of CI 
 Scenario 1 (external thyroid dose) Scenario 2 (total thyroid dose) 
Method Conventional regression Bayesian method 
Conventional 
regression Bayesian method 
“True” slope 
(ERR/Gy) 
Mean 
dosea 
Median 
doseb Original
c CMd CMDe Mean dosea 
Median 
doseb Original
c CMd CMDe 
20 5.73 6.21 7.68 7.79 8.27 2.83 6.00 9.62 11.64 13.20 
12 3.96 4.31 4.97 5.06 5.38 1.80 3.90 6.02 7.33 8.24 
3 2.00 2.18 2.14 2.21 2.34 0.51 1.53 2.12 2.42 2.85 
Overall 3.90 4.23 4.93 5.02 5.33 1.72 3.81 5.92 7.13 8.09 
Relative upper bound of CI (=UCL/Est.) 
 Exposure Scenario 1 (external thyroid dose) Exposure Scenario 2 (total thyroid dose) 
Method Conventional regression Bayesian method 
Conventional 
regression Bayesian method 
“True” slope 
(ERR/Gy) 
Mean 
dosea 
Median 
doseb Original
c CMd CMDe Mean dosea 
Median 
doseb Original
c CMd CMDe 
20 1.31 1.31 1.43 1.43 1.42 1.37 1.33 1.71 1.76 1.71 
12 1.35 1.35 1.47 1.46 1.46 1.38 1.34 1.82 1.83 1.79 
3 1.71 1.71 1.81 1.76 1.76 1.52 1.44 2.13 2.09 1.99 
Overall 1.46 1.46 1.57 1.55 1.55 1.42 1.37 1.89 1.89 1.83 
Conventional regression analysis using a single dose vector of 2,376 doses (one per subject) 
(a) individual mean doses 
(b) individual median doses 
 
Bayesian Model Averaging using 4,999 cohort dose vectors of 2,376 doses (one per subject per vector) 
(c) simulated individual doses (Original) 
(d) conditional individual mean doses (CM) 
(e) conditional individual median doses (CMD) 
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Figure 1. 
 
Figure 2. 
 
 
 
 
 
 
 
 
 
 31 
 
Figure 3. 
 
Figure 4. 
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Figure 5. 
 
Figure 6. 
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Figure S1 
 
 Figure S1.  Results of 30 simulation tests for Scenario 1 (external thyroid dose) comparing the 
dose response analysis for conventional regression using a single vector of individual mean and 
individual median doses, with a Bayesian dose response using 4,999 vectors of conditional 
individual median doses. Results are normalized to a true ERR/Gy of 12 (i.e., results that 
reproduce the true ERR/Gy will equal 1.0). 
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Figure S2. Results of 30 simulation tests for Scenario 2 (total thyroid dose) comparing the dose 
response analysis for conventional regression with a single vector of mean and median doses, 
with a Bayesian dose response using 4,999 vectors of conditional individual median doses. 
Results are normalized to a true ERR/Gy of 12 (i.e., results that reproduce the true ERR/Gy will 
equal 1.0). 
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Appendix S1. Relationship between our problem and Bayesian model uncertainty 
paradigm 
Under our model uncertainty paradigm, we rely on Bernardo and Smith’s (34) perspectives of M-
closed, M-complete, and M-open for the relationship between the multiple realizations of dose 
vectors produced from the 2DMC algorithm and the true exposure model. The M-closed 
perspective is the situation in which the dose reconstruction method describes the ‘true’ exposure 
model exactly and thus is able to produce the true exposure in one of its multiple realizations of 
possibly true dose vectors. Under M-complete, the ‘true’ exposure model exists but the 2DMC 
algorithm is unable to reproduce the true dose vector exactly. However, a few of the 2DMC 
realizations of a possibly true dose vector should be reasonable approximations of the true 
exposure and, thus, we are able to evaluate and compare each of the alternative realizations of 
dose vectors. The M-open perspective is similar to the M-complete; the difference is that we 
cannot assume that the true exposure model is captured within the multiple realizations of dose 
vectors produced by the 2DMC dose estimation algorithm. In that case, we cannot develop any 
prior beliefs about the probability that each realization of 2DMC is equal to the true exposure 
model without having additional information. Most dose estimations for cohorts supporting 
epidemiologic studies are located somewhere between the extremes of the perspectives of M-
complete and M-open, since we cannot guarantee that the dosimetry system generates the true 
dose vector.  
 
Appendix S2. Stochastic Approximation Monte Carlo (SAMC) 
We give a brief review of the SAMC method (33). We can reformulate the posterior 
distribution in terms of U(), the energy function: 
p(α,,|Data) = exp(-U(α,,))/Z, (α,,) , 
where Z is the normalizing constant and  is the parameter space. Let  denote a set of 
parameters, =(1,…, J, , ) and . When we write U()=-log(p0(|Data)), where p0() is 
the unnormalized posterior distribution, then U is equivalent to the negative of the log-posterior 
distribution in Bayesian computation.  
Without loss of generality we assume  is compact. In the implementation we set =[-
10100,10100]. We assume that the parameter space can be partitioned according to the energy 
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function, U(), into S disjoint sub-regions denoted by E1={(): U()≤u1}, E2={(): 
u1<U()≤u2},…, E(S-1)={(): u(S-2)<U()≤u(S-1)}, ES={(): U()>u(S-1)}, where u1,..,u(S-1) are real 
numbers in increasing order and are specified by the user. The SAMC method tries to sample 
from each sub-region with a pre-specified frequency, f=(f1,…,fS) (e.g., equal frequency) using 
the trial distribution ,)()()(
1
0


S
s
s
s
s
w EIw
pfp  where I() denotes an indicator function and 
 dpw
sE
s  )(0  for s=1,…,S.  
Since our problem involves parameter estimation with multiple models, (i.e., K linear 
dose-response models according to K dose vectors), the model space can be partitioned into K 
disjoint sub-regions (E1,..., EK). We use the SAMC model selection approach. We emphasize that 
our main interest is estimation of the slope of the linear dose response, , (ERR Gy-1), not the 
selection of different types of dose-response models with different shapes that depart from linear. 
We attempt to identify which among multiple dose vectors is a good approximate for the 
unknown true dose vector in this study. We illustrate how we implemented the SAMC method. 
Let K models denote M1, …, MK, each of which are associated with one of the K dose vectors. 
The SAMC method consists of two stages: (1) Metropolis-Hastings (MH) sampling of  and (2) 
weight updating. The weight, ),...,( 1 K  , denotes the working estimate of (log(w1/f1),…, 
log(wK/fK)) obtained at each iteration.  
In MH sampling, we generate a sample (t) from a Metropolis-Hastings kernel ),( )()( tw tK  with 
the proposal distribution q((t),) and the stationary distribution, ,)()()(
1
0
)()( 


K
k
kEI
e
pp t
k
t  
where ),...,( )()(1
)( t
K
tt    at iteration t. Let )( ji MMQ   denote the proposed probability for a 
transition from model Mi to model Mj. The proposed distribution satisfies irreducibility and 
aperiodicity for convergence.  
First, generate dose vector selection parameter, *, according to the proposal )( )1(    MMQ t  at 
iteration t. If *=(t-1), then generate * and * from ),,|,( )1( tvectordoseyXp  by a single 
 37 
 
MCMC iteration and set (t, t, t)= (*, *, *). If *(t-1), then generate * and * from 
),,|,(  vectordoseyXp and accept *, * and * with probability  
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In the weight updating stage, *= (t-1) + t(et-f), where t denotes the gain factor sequence and et 
= ),...,( )()(1
t
K
t ee  and 1)( tke  if (t)=k and 0 otherwise. The gain factor sequence should be a 
positive, non-decreasing sequence satisfying the following conditions: 
0t
t  and 
,)(
0

t
t   for some (1,2). More details on the implementation of SMAC are described in 
Liang et al. (33). 
 
 
 
 
 
 
 
 
